Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Public ClinicalTrials.gov record NCT01421524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/1b, Multi-center, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma.
Study identification
- NCT ID
- NCT01421524
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Celgene
- Industry
- Enrollment
- 271 participants
Conditions and interventions
Conditions
Interventions
- CC-122 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 11, 2011
- Primary completion
- Nov 20, 2023
- Completion
- Nov 20, 2023
- Last update posted
- Dec 11, 2023
2011 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Cancer Center | Duarte | California | 91010-300 | — |
| UCLA Neuro-Oncology Program | Los Angeles | California | 90095 | — |
| UCSF Helen Diller Medical Center at Parnassus Heights | San Francisco | California | 94143-1270 | — |
| University Of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Medical Center - New Center One | Detroit | Michigan | 48202-268 | — |
| Comprehensive Cancer Centers Of Nevada | Las Vegas | Nevada | 89169 | — |
| Rutgers Cancer Institute of New Jersey University | New Brunswick | New Jersey | 08901 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| Local Institution - 020 | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| MUSC Rheumatology and Immunology Dept. | Charleston | South Carolina | 29425 | — |
| Greenville Hospital System | Greenville | South Carolina | 29605 | — |
| Sarah Cannon Research Institute Drug Development Unit | Nashville | Tennessee | 37203 | — |
| Texas Oncology, PA - Dallas 75246 | Dallas | Texas | 75246 | — |
| South Texas Accelerated Research Therapeutics (START) | San Antonio | Texas | 78229 | — |
| Swedish Medical Center Cancer Institute Research | Seattle | Washington | 98104 | — |
| Yakima Valley Memorial Hospital/ North Star Lodge | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01421524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 11, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01421524 live on ClinicalTrials.gov.